Asian Penny Stocks To Watch In August 2025

As global markets face uncertainty due to renewed tariffs and trade policy challenges, investors are increasingly seeking opportunities in less conventional areas. Penny stocks, while an older term, continue to highlight smaller or newer companies with potential for significant growth. By focusing on those with strong financials and solid fundamentals, investors can uncover hidden gems that might offer stability and upside in the current market landscape.

Top 10 Penny Stocks In Asia

Click here to see the full list of 988 stocks from our Asian Penny Stocks screener.

We'll examine a selection from our screener results.

NagaCorp (SEHK:3918)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: NagaCorp Ltd. is an investment holding company involved in managing and operating a hotel and casino complex in Cambodia, with a market cap of HK$17.74 billion.

Operations: The company's revenue is primarily derived from its casino operations, which generated $542.56 million, complemented by $24.51 million from hotel and entertainment services.

Market Cap: HK$17.74B

NagaCorp Ltd. has demonstrated financial resilience with its short-term assets exceeding long-term liabilities and a debt-to-equity ratio reduced significantly over five years. The company's operating cash flow effectively covers its debt, highlighting strong liquidity management. However, challenges persist as short-term liabilities surpass current assets, and recent earnings have declined by 38.3% year-on-year due to significant one-off losses of $48.9M impacting results for the last fiscal year ending December 2024. Despite these hurdles, earnings are forecasted to grow annually by 29%, suggesting potential recovery prospects in the near term amidst stable board leadership transitions.

• Click here to discover the nuances of NagaCorp with our detailed analytical financial health report.
• Examine NagaCorp's earnings growth report to understand how analysts expect it to perform.

Uni-Bio Science Group (SEHK:690)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Uni-Bio Science Group Limited is an investment holding company that researches, develops, manufactures, and sells biological and chemical pharmaceutical products for treating human diseases in the People's Republic of China with a market cap of HK$895.68 million.

Operations: The company generates revenue from two primary segments: Chemical Pharmaceutical Products, contributing HK$249.62 million, and Biological Pharmaceutical Products, accounting for HK$303.36 million.

Market Cap: HK$895.68M

Uni-Bio Science Group, with a market cap of HK$895.68 million, has shown promising developments in its pharmaceutical pipeline, notably the acceptance of Isavuconazonium Sulfate Capsules by China's NMPA for antifungal treatments. The company benefits from strong financial health with short-term assets exceeding liabilities and a high return on equity at 25.4%. Despite increased debt-to-equity over five years to 32.1%, cash reserves surpass total debt, ensuring robust liquidity. Recent product launches in ophthalmology and medical aesthetics further diversify revenue streams and strengthen market positioning amid stable earnings growth outpacing industry averages.

• Take a closer look at Uni-Bio Science Group's potential here in our financial health report.
• Evaluate Uni-Bio Science Group's historical performance by accessing our past performance report.

AIRA Capital (SET:AIRA)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: AIRA Capital Public Company Limited, along with its subsidiaries, operates in investment and financial advisory services in Thailand and has a market capitalization of THB8.53 billion.

Operations: AIRA Capital's revenue is primarily derived from its Securities and Investment Business (THB320 million), Property Development (THB280 million), Factoring (THB128 million), Rental and Service Business excluding Property Development (THB63 million), and Advisory and Investment Banking services (THB14 million).

Market Cap: THB8.53B

AIRA Capital, with a market capitalization of THB8.53 billion, operates across several sectors including securities and investment, property development, and factoring. Despite being unprofitable with increasing losses over the past five years, AIRA maintains a stable cash runway exceeding three years due to its free cash flow. The company’s seasoned management and board bring significant experience to navigate challenges associated with high debt levels (net debt to equity ratio at 84.5%). While short-term assets cover both short- and long-term liabilities comfortably, share price volatility remains high compared to peers in the Thai market.

• Dive into the specifics of AIRA Capital here with our thorough balance sheet health report.
• Examine AIRA Capital's past performance report to understand how it has performed in prior years.

Key Takeaways

• Get an in-depth perspective on all 988 Asian Penny Stocks by using our screener here.
• Seeking Other Investments? Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com